يعرض 1 - 10 نتائج من 10 نتيجة بحث عن '"Adlard, NE"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية
    HPR62 Equity and Outcome Events in Patients With Hidradenitis Suppurativa: Exploring Effect Modifiers Associated With HS Diagnostic Delay

    المؤلفون: Truman, I, Milligan, G, Modi, H, Murray, N, Adlard, NE

    المصدر: In Value in Health December 2022 25(12) Supplement:S243-S244

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

    المؤلفون: Farhane, F, Bhan, V, Clift, F, Baharnoori, M, Thomas, K, Patel, BP, Blanchette, F, Adlard, NE, Vudumula, U, Gudala, K, Dutta, N, Grima, D, Mouallif, S

    المصدر: In Value in Health December 2022 25(12) Supplement:S55-S56

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    POSA148 Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

    المؤلفون: Mouallif, S, Thomas, K, Adlard, NE, Cooney, P, Blanchette, F, Patel, BP, Baharnoori, M, Bhan, V, Clift, F, Grima, D

    المصدر: In Value in Health January 2022 25(1) Supplement:S63-S63

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    PND131 - PATIENT PREFERENCES FOR DIFFERENT MODES AND FREQUENCY OF ADMINISTRATION OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES

    المؤلفون: Adlard, NE, Panpurina, A, Patel, VJ, Khurana, V, Medin, J, Kubara, A

    المصدر: In Value in Health October 2018 21 Supplement 3:S351-S351

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    PND130 - MEASURING WHAT MATTERS TO PEOPLE WITH MULTIPLE SCLEROSIS AND PREFERENCES FOR NOVEL METHODS TO ASSESS CLINICAL OUTCOMES

    المؤلفون: Adlard, NE, Panpurina, A, Patel, VJ, Khurana, V, Medin, J, Kubara, A

    المصدر: In Value in Health October 2018 21 Supplement 3:S350-S351

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    PND127 - QUALITY OF LIFE IN PAEDIATRIC MULTIPLE SCLEROSIS: SYSTEMATIC LITERATURE REVIEW

    المؤلفون: Steeves, S, Beaver, S, Ashworth, L, Summers, J, Adlard, NE, Kroes, M

    المصدر: In Value in Health October 2018 21 Supplement 3:S350-S350

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK: THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

    المؤلفون: Adlard, NE, Watson, J, Bottomley, CJ, Kroes, M

    المصدر: In Value in Health October 2018 21 Supplement 3:S348-S348

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    المؤلفون: Adlard, NE, Rendas-Baum, R., Bjorner, JB, Rychlec, K, Khurana, V, Medin, J

    المصدر: In Value in Health October 2018 21 Supplement 3:S390-S390

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE—A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA

    المؤلفون: Morgan, C, Adlard, NE, Carroll, SM

    المصدر: In Value in Health 2010 13(7):A369-A369

    View record from ScienceDirect View record at Wiley Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.

    المؤلفون: Noon KM; a Costello Medical Consulting Ltd , London , UK., Montgomery SM; b Costello Medical Consulting Ltd , Cambridge , UK., Adlard NE; c Novartis Pharma AG , Basel , Switzerland., Kroes MA; d Novartis Pharmaceuticals UK Ltd , Surrey , UK.

    المصدر: Journal of medical economics [J Med Econ] 2018 Oct; Vol. 21 (10), pp. 983-992. Date of Electronic Publication: 2018 Jul 05.

    نوع المنشور: Journal Article

    بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

    مواضيع طبية MeSH: Models, Economic*, Immunosuppressive Agents/*economics , Immunosuppressive Agents/*therapeutic use , Multiple Sclerosis, Relapsing-Remitting/*drug therapy , Technology Assessment, Biomedical/*methods, Adult ; Alemtuzumab/economics ; Alemtuzumab/therapeutic use ; Cost-Benefit Analysis ; Dimethyl Fumarate/economics ; Dimethyl Fumarate/therapeutic use ; Female ; Fingolimod Hydrochloride/economics ; Fingolimod Hydrochloride/therapeutic use ; Health Resources/economics ; Health Resources/statistics & numerical data ; Health Services/economics ; Health Services/statistics & numerical data ; Humans ; Male ; Markov Chains ; Natalizumab/economics ; Natalizumab/therapeutic use

    PDF full text from Publisher
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء